Serum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: Can they serve as potential early biomarkers for atherosclerosis?

Experimental and Toxicologic Pathology

Volumn 67, Issue 9, 2015, Pages 459-466

  Korolenko, T A ^a   Pisareva, E E ^a   Filyushina, E E ^a   Johnston, T P ^b   Machova, E ^c  

^a SCIENTIFIC RESEARCH INSTITUTE OF PHYSIOLOGY AND BASIC MEDICINE   (Russian Federation)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Beta glucan; Biomarkers; Chitotriosidase; Cystatin C; Dyslipidemia; Macrophages

Indexed keywords

BETA 1,3 GLUCAN; CHITINASE; CHITOTRIOSIDASE; CHITOTRIOSIDASE 1; CHOLESTEROL; CYSTATIN C; GADOLINIUM CHLORIDE; POLOXAMER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL DENSITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ELECTRON MICROSCOPY; ENZYME ACTIVITY; LEUKOCYTE; LYSOSOME; MACROPHAGE; MALE; MORPHOLOGY; MORPHOMETRICS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CBA MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EARLY DIAGNOSIS; ENZYMOLOGY; LIVER; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; BIOMARKERS; CYSTATIN C; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; EARLY DIAGNOSIS; HEXOSAMINIDASES; LIPIDS; LIVER; MALE; MICE, INBRED CBA; POLOXAMER;

EID: 84941191417     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2015.06.003     Document Type: Article

References (35)

1. Aerts J.M., Hollak C.E. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin. Hematol. 1997, 10(4):691-709. PubMed 9497858.
2. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563(Pt.1):23-60. PubMed 15611012.
3. Artieda M., Cenarro A., Gañán A., Jerico I., Gonzalvo C., Casado J.M., Vitoria I., Puzo J., Pocovi M., Civeira F. Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. Arterioscler Thromb. Vasc. Biol. 2003, 23(9):1645-1652. PubMed 12893688.
4. Artieda M., Cenarro A., Gañán A., Lukic A., Moreno E., Puzo J., Pocovi M., Civeira F. Serum chitotriosidase activity, a marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein. Cardiology 2007, 108(4):297-306. Pubmed 17290100.
5. Bengtsson E., To F., Grubb A., Hakansson K., Wittgren L., Nilsson J., Jovinge S. Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 2005, 180(1):45-53. PubMed 15823274.
6. de Boer I.H., Astor B.C., Kramer H., Palmas W., Seliger S.L., Shipak M.G., Siscovick D.S., Tsai M.Y., Kestenbaum B. Lipoprotein abnormalities associated with mild impairment of kidney function in the Multi-Ethnic Study of Atherosclerosis. Clin. J. Am. Soc. Nephrol. 2008, 3(1):125-132. PubMed 18057305.
7. de Boer I.H., Katz R., Cao J.J., Fried L.F., Kestenbaum B., Mukamal K., Rifkin D.E., Sarnak M.J., Shlipak M.G., Siscovick D.S., Cystatin C. albuminuria, and mortality among older adults with diabetes. Diabetes Care 2009, 32(10):1833-1838. PubMed 9587367.
8. Dergunova M.A., Alexeenko T.V., Zhanaeva S.Y., Filyushina E.E., Buzueva I.I., Kolesnikova O.P., Kogan G., Korolenko T.A. Characterization of the novel chemically modified fungal polysaccharides as the macrophage stimulators. Int. Immunopharmacol. 2009, 9(6):729-733. PubMed 19268718.
9. Doganer Y.C., Aydogan U., Aydogdu A., Aparci M., Akbulut H., Nerkiz P., Turker T., Cayci T., Barcin C., Saglam K. Relationship of cystatin C with coronary artery disease and its severity. Coron Artery Dis. 2013, 24(2):119-126. PubMed 23211477.
10. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., Silverstein R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 2000, 105(8):1049-1056. PubMed 10772649.
11. Frendeus K.H., Wallin H., Janciauskiene S., Abrahamson M. Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int. J. Biochem. Cell Biol. 2009, 41(11):2262-2269. PubMed 19446036.
12. Guo Y., He W., Boer A.M., Wevers R.A., de Bruijn A.M., Groener J.E., Hollak C.E., Aerts J.M., Galjaard H., van Diggelen O.P. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J. Inherit Metab. Dis. 1995, 18(6):717-722. PubMed 8750610.
13. Johnston T.P., Baker J.C., Hall D., Jamal S., Palmer W.K., Emeson E.E. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 2000, 149:303-313. PubMed 10729380.
14. Johnston T.P., Coker J.W., Paigen B.J., Tawfik O. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis. J. Cardiovasc Pharmacol. 2002, 39:404-411. PubMed 11862120.
15. Johnston T.P. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J. Cardiovasc Pharmacol. 2004, 43(4):595-606. PubMed 15085072.
16. Johnston T.P., Jaye M., Webb C.L., Krawiec J.A., Alom-Ruiz S.P., Sachs-Barrable K., Wasan K.M. Poloxamer 407 (P-407)-mediated reduction in the gene expression of ATP-binding-cassette transporter A1 may contribute to increased cholesterol in peripheral tissues of P-407-treated rats. Eur. J. Pharmacol. 2006, 536(3):232-240. PubMed 16603153.
17. Johnston T.P., Zhou X. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect. J. Cardiovasc Pharmacol. 2007, 49(4):246-252. PubMed 17438410.
18. Kanneganti M., Kamba A., Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J. Epithel. Biol. Pharmacol. 2012, 5:1-9. PubMed 23439988.
19. Kaur G., Levy E. Cystatin C in Alzheimer's disease. Front Mol. Neurosci. 2012, 5:1-11. PubMed 22783166. 10.3389/fnmol.2012.00079.
20. Keller T., Messow C.M., Lubos E., Nicaud V., Wild P.S., Rupprecht H.J., Bickel C., Tzikas S., Peetz D., Lackner K.J., Tiret L., Munzel T.F., Blankenberg S., Schnabel R.B. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur. Heart J. 2009, 30:314-320.
21. Kishimoto Y., Tani M., Uto-Kondo H., Lizuka M., Saita E., Sone H., Kurata H., Kondo K. Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages. Eur. J. Nutr. 2010, 49(2):119-126. PubMed 19784539.
22. Kologlu T., Ucar S.K., Levent E., Akcay Y.D., Coker M., Sozmen E.Y. Chitotriosidase as a possible marker of clinically evidenced atherosclerosis in dyslipidemic children. J. Pediatr. Endocrinol. Metab. 2014, 27(7-8):701-708. Pubmed 24572981.
23. Korolenko T.A., Zhanaeva S.Y., Falameeva O.V., Kaledin V.I., Filyushina E.E., Buzueva I.I., Paul G.A. Chitotriosidase as a marker of macrophage stimulation. Bull. Exp. Biol. Med. 2000, 130(10):948-950. PubMed 11177289.
24. Korolenko T.A., Dergunova M.A., Alexeenko T.V., Zhanaeva S.Y., Filyushina E.E., Filatova T.G. lntralysosomal accumulation of gadolinium and lysosomal damage during selective depression of liver macrophages in vivo. Bull. Exp. Biol. Med. 2006, 142(4):391-394. PubMed 17415418.
25. Korolenko T.A. Cystatins: biological role and changes in pathology. Vestn Ross Akad Med. Nauk 2008, 4:43-47. PubMed 18488456.
26. Korolenko T.A., Tuzikov F.V., Cherkanova M.S., Johnston T.P., Tuzikova N.A., Loginova V.M., Filyushina E.E., Kaledin V.I. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407. Can. J. Physiol. Pharmacol. 2012, 90(2):141-153. PubMed 22320860.
27. Korolenko T.A., Tuzikov F.V., Johnston T.P., Tuzikova N.A., Kisarova Y.A., Zhanaeva S.Y., Alexeenko T.V., Zhukova N.A., Brak I.V., Spiridonov V.K., Filyushina E.E., Cherkanova M.S., Monoszon A.A. The influence of repeated administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart. Can. J. Physiol. Pharmacol. 2012, 90(11):1456-1468. PubMed 23181274.
28. Lutgens S.P., Cleutjens K.B., Daemen M.J., Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007, 21(12):3029-3041. PubMed 17522389.
29. Monoszon A.A., Cherkanova M.S., Duzhak A.B., Korolenko T.A. Chitotriosidase activity in the blood serum and organs of mice of various strains under the influence of chitin. Bull. Exp. Biol. Med. 2012, 154(1):40-43.
30. Palmer W.K., Emeson E.E., Johnston T.P. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998, 136(1):115-123. PubMed 9544738.
31. Qin Y., Shi G.P. Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases. Pharmacol. Ther. 2011, 131(3):338-350. PubMed 21605595.
32. Radhika A., Sudhakaran P.R. Upregulation of macrophage-specific functions by oxidized LDL: lysosomal degradation-dependent and -independent pathways. Mol. Cell. Biochem. 2013, 372(1-2):181-190. PubMed 23054190.
33. van Eijk M., van Roomen C.P., Renkema G.H., Bussink A.P., Andrews L., Biommaart E.F., Sugar A., Verhoeven A.J., Boot R.G., Aerts J.M. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int. lmmunol. 2005, 17(11):1505-1512. PubMed 16214810.
34. Warren A., Benseler V., Cogger V.C., Bertolino P., Le Couteur D.G. The impact of poloxamer 407 on the ultrastructure of the liver and evidence for clearance by extensive endothelial and Kupffer cell endocytosis. Toxicol. Pathol. 2011, 39(2):390-397. Pubmed 21257999.
35. Yu C.H., Dai X.Y., Chen Q., Zang J.N., Deng L.L., Liu Y.H., Ying H.Z. Hypolipidemic and antioxidant activities of polysaccharides from Rosae Laevigatae Fructus in rats. Carbohydr. Polym. 2013, 94(1):56-62. PubMed 23544509.